Key Drivers
- Margin pressure
- Strong liquidity
- Negative cash flow
AIAI Summary
TWST is transitioning from a “promising platform” story to an execution test as triple-digit AI order growth, 14 straight quarters of revenue growth, and guidance toward Q4 EBITDA breakeven improve the thesis, but with the stock already priced for success, the key takeaway is to watch whether revenue conversion and margin gains can outpace dilution and justify the valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin pressure
- •Strong liquidity
- •Negative cash flow
TWST has solid gross profit and liquidity, but persistent operating losses, negative free cash flow, and a rich sales valuation make the stock high risk until margins improve.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Clean breakouts
- •Overextended run
TWST has surged over the last month with higher lows and breakouts above $100 and $115, but after a fast run into $125.29 it now needs follow-through above resistance to avoid mean reversion.
Sharp advance from $93.85 to $118.57 with a fast rally off the $85.47 pivot low increases mean reversion risk
Sentiment & News
Key News Insights:
- •Revenue Acceleration
- •Capital Raise
- •Profitability Gap
Twist Bioscience posted 23% Q3 revenue growth, raised full-year guidance, and strengthened its balance sheet with a $300 million offering, but ongoing losses keep profitability on the radar.
The news is modestly positive overall, as strong growth and higher guidance support the stock, though dilution and continued losses temper the upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings